The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck spends $10 billion for Verona, gaining access to its COPD medication Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

A new type of fuel cell that runs on sodium metal could one day help clean up sectors where it’s difficult to replace fossil fuels, like rail, regional aviation, and short-distance shipping.

A Bar-Ilan University study has found that individuals with sodium levels at the higher end of the "normal" range are significantly more likely to develop hypertension and heart failure, two of ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Merck (NYSE: MRK) recently announced its first-quarter results, exceeding Wall Street’s expectations for both earnings and revenue. The company reported revenues of $15.53 billion and adjusted ...

A low sodium diet limits high sodium foods and beverages. Healthcare professionals typically recommend these diets to treat conditions such as high blood pressure or heart disease.

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 adjusted earnings projection, partly to account for recently imposed ...

Halozyme alleges in a lawsuit that a subcutaneous formulation of Merck’s popular cancer drug Keytruda infringes 15 of its patents.